Prior Authorization Denied? Your 2026 GLP-1 Appeal Playbook
The most common denial reasons, what each means for your appeal, the step-by-step internal and external review process, and when a cash-pay bridge makes more sense than waiting.
Prior authorization denial for a GLP-1 medication is more common than it should be — and more appealable than most people realize. Here's the 2026 playbook for getting a PA denial overturned.
Why PAs get denied (and what each means for your appeal)
| Denial reason | Appeal approach |
|---|---|
| BMI doesn't meet threshold | Verify the measurement used. Plans often require BMI ≥30 or ≥27 + comorbidity. If you have comorbidities, confirm they're documented in the PA. |
| Step therapy required first | Request the step therapy exception. Your prescriber must document that you've tried and failed (or have a contraindication to) the required prior medications. |
| Diagnosis code mismatch | E66.x is obesity; E11.x is T2D. If your prescriber submitted under the wrong indication for your plan's covered diagnosis, a resubmission with corrected coding often resolves this. |
| Not medically necessary | This is the broadest denial and the most appealable. Your prescriber should submit a letter of medical necessity documenting obesity-related comorbidities, failed interventions, and clinical rationale. |
| Prior authorization form incomplete | A second submission with complete documentation often resolves this — not a true clinical denial. |
The appeal process, step by step
Standard PA appeal workflow
- Request the denial in writing — insurers must provide the specific reason
- Review your plan's Explanation of Benefits (EOB) for the exact denial code
- Contact your prescriber — they need to initiate or support the appeal
- File a first-level internal appeal within your plan's deadline (typically 60–180 days from denial)
- Request an expedited appeal if medically urgent (insurer must respond within 72 hours vs. 30–60 days standard)
- If internal appeal fails, request external review — required by ACA for most plans, uses an independent reviewer
- If external review fails, file a state insurance commissioner complaint (creates regulatory pressure)
Your prescriber's letter of medical necessity is the most important document in the appeal. It should: document your BMI with measurement date, list all obesity-related comorbidities with ICD-10 codes, describe what dietary/behavioral interventions have been tried and their outcomes, and explain the clinical rationale for GLP-1 specifically. Generic letters fail; specific clinical documentation wins.
When to skip the appeal and go cash-pay
Appeal timelines run 30–60 days for standard review, 72 hours for expedited. If you need medication sooner, starting on a cash-pay compounded GLP-1 while the appeal proceeds is a reasonable parallel path. SHED's compounded semaglutide at $297–299/month starting dose is the most common bridge option — note that pricing increases to $399/month at the 7.5mg dose and above.
Verified telehealth providers
Telehealth prescribers experienced in PA submission and appeals documentation.
Paid link Get started →Cash-pay bridge while your insurance appeal proceeds. Semaglutide from $297/mo (increases to $399 at 7.5mg+).
Paid link Get started →